Brentuximab -- First-Line Option in Elderly Hodgkin's Lymphoma

A phase 2 trial has shown that brentuximab vedotin monotherapy is safe and effective as first-line therapy in elderly lymphoma patients who cannot tolerate standard chemotherapy.